FibroGen, Inc. is a US-based biopharmaceutical company specializing in discovering, developing, and commercializing innovative therapeutics to address serious unmet medical needs. Its lead product, Roxadustat, is an oral small molecule that inhibits hypoxia-inducible factor prolyl hydroxylase, enhancing red blood cell production to treat anemia in chronic kidney disease and chemotherapy-induced anemia. The company’s pipeline includes promising candidates like FG-3246, a first-in-class antibody-drug conjugate targeting CD46, aimed at treating metastatic castration-resistant prostate cancer and other tumors. Established in 1993 and headquartered in San Francisco, California, FibroGen collaborates with major pharmaceutical partners such as Astellas Pharma and AstraZeneca. It plays a significant role in oncology and hematology, leveraging the body's natural pathways to develop treatments for life-threatening conditions, reflecting its commitment to pioneering therapies at the forefront of cancer research.